Literature DB >> 2521818

Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor.

M Heras1, J H Chesebro, W J Penny, K R Bailey, L Badimon, V Fuster.   

Abstract

The effect of recombinant hirudin and the dosage of heparin on acute platelet-thrombus deposition during carotid angioplasty in anesthetized pigs was prospectively assessed. Fifty-five animals (mean weight, 33.9 kg) were randomized to one of six heparin dosages: heparin boluses of 35, 50, 100, 150, 200, or 250 units/kg followed by a continuous infusion of 35, 50, 100, 150, 200, or 250 units/kg/hr, respectively. Another five pigs received a bolus of 1 mg/kg hirudin (recombinant desulphatohirudin), a specific thrombin inhibitor, followed by an infusion of 1 mg/kg/hr. Bilateral carotid angioplasty was performed in all pigs 20 minutes after starting the infusion; they were sacrificed 57 +/- 12 minutes after the procedure. Deep medial arterial injury was present in approximately 75% of the dilated segments, and subendothelial injury in the remaining 25%. Mean log of number of platelets and molecules of fibrinogen per centimeter squared of deep injury in segments from all the animals treated with heparin were 4.74 +/- 1.03 and 5.02 +/- 0.64, respectively. A regression analysis showed an inverse correlation of the log of platelet deposition with the heparin group (r = -0.56, p = 0.0001) with administered total units of heparin (r = -0.55, p = 0.0003) and with mean plasma heparin concentration (r = -0.55, p = 0.0004) in deeply injured arteries. Similar inverse relations were obtained for fibrinogen. In contrast, the deposition of platelets and fibrinogen in subendothelial injury was very low and independent of the heparin administered.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521818     DOI: 10.1161/01.cir.79.3.657

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  39 in total

1.  Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.

Authors:  A B Kelly; J M Maraganore; P Bourdon; S R Hanson; L A Harker
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

Review 3.  Characterization of a functional thrombin receptor. Issues and opportunities.

Authors:  S R Coughlin; T K Vu; D T Hung; V I Wheaton
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

4.  Current status of thrombolytic therapy in acute myocardial infarction.

Authors:  B Stein; R Roberts
Journal:  Tex Heart Inst J       Date:  1991

Review 5.  Restenosis after angioplasty.

Authors:  A H Gershlick; D P de Bono
Journal:  Br Heart J       Date:  1990-12

6.  Thrombin Hypothesis: The TIMI 9B and GUSTO IIB Trials Have Successfully Disproven/Proven the Thrombin Hypothesis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

7.  Adjunctive Therapy with an Antithrombotic Drug Can Prevent Reocclusion and Induce Residual Thrombus Reduction After Percutaneous Transcatheter Angioplasty of the Thrombotic Lesions.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 8.  Hirudin, a new therapeutic tool?

Authors:  J Bichler; H Fritz
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

Review 9.  New anticoagulant strategies. Current status and future potential.

Authors:  J Weitz
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

10.  Tissue factor is rapidly induced in arterial smooth muscle after balloon injury.

Authors:  J D Marmur; M Rossikhina; A Guha; B Fyfe; V Friedrich; M Mendlowitz; Y Nemerson; M B Taubman
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.